Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.

World J Cardiol · 2022 · PMC9258221 · PMID 35979179

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

In an exploratory analysis of AMPLITUDE-O with GLP-1RA efpeglenatide ( n = 618), a nonsignificant trend ( P interection = 0.35) of greater HHF reduction was observed in baseline efpeglenatide plus SGLT-2I users (HR = 0.23; 95%CI: 0.05-0.97) vs SGLT-2I non-users (HR = 0.70; 95%CI: 0.42-1.17)[ 45 ].

also in 5,406 other papers

nominally significantno p-value reported

Notably, a propensity matched post hoc analysis ( n = 1144) of EXSCEL reported a nominally significant reduction in all-cause mortality (adjusted HR = 0.38, 95%CI: 0.16-0.90) and CV death (adjusted HR = 0.17; 95%CI: 0.04-0.77) and improvement in estimated eGFR slope (adjusted HR = +1.94 mL/min; 95%CI: 0.94-2.94 mL/min/1.73 m 2 /year) with exenatide QW plus SGLT-2I combination therapy compared to the placebo[ 43 ].

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.